About three-quarters of infectious disease physicians in North America said they favored HIV pre-exposure prophylaxis (PrEP), but only 9% reported that they had prescribed Truvada (tenofovir/emtricitabine) for this purpose, according to a report in the December 6, 2013, advance edition of Clinical Infectious Diseases.
Published: January 10, 2014
PrEP refers to using antiretroviral drugs to prevent HIV from establishing infection after exposure. The FDA approved Truvada for PrEP in July 2012.
The iPrEx study of gay/bisexual men and transgender women showed that once-daily Truvada PrEP reduced the risk of new HIV infections by 42% overall, and by more than 90% among participants with measurable blood drug levels. Likewise, the Partners PrEP and TDF2 trials found that daily Truvada reduced the incidence of new infections among heterosexual couples, while the Bangkok Tenofovir Study showed that PrEP using tenofovir alone reduced the risk of HIV acquisition by half among people who inject drugs. Results have not been as good, however, in studies of PrEP for women in Africa due to low adherence.
In June 2013, Maile Karris from the University of California at San Diego and colleagues conducted a survey of infectious diseases physicians’ opinions and practice regarding PrEP through the Emerging Infections Network (EIN), a CDC-funded sentinel network of more than 1000 infectious disease specialists, mostly in North America.
Full text of article available at link below –